The Casi Pharmaceuticals-backed immunotherapy developer has completed a $63m series C round co-led by CICC and Oceanpine Capital.
Juventas Cell Therapy, a China-based immunotherapy developer which counts pharmaceutical firm Casi Pharmaceuticals as a backer, has closed a $63m series C round, it has revealed.
The company had announced in July this year it has raised over $60m in a round co-led by Oceanpine Capital and China International Capital Corporation subsidiary CICC Capital that included Jiadao Private Capital, Redhill Capital, Delian Capital, Tianjin Venture Capital, Dalton Capital and Rfund.
Founded in 2018, Juventas is developing immuno-oncological treatments for blood…
